
    
      Study completed as per protocol. 'Switched to commercial drug' implies that after the primary
      and secondary objectives were achieved, one patient continued the study treatment as they did
      not meet the progression disease or AE to be discontinued from the treatment. But after the
      regulatory approval, Novartis decided to close the study, the 1 patient switched to
      commercially available drug.
    
  